Back to News
Market Impact: 0.35
H.I.G. Is Said to Consider Sale of $1 Billion Drugmaker Rising Pharma
Source: Bloomberg
M&A & RestructuringCompany FundamentalsManagement & Governance
H.I.G. Capital is exploring strategic options for its controlling stake in Rising Pharmaceuticals, including a possible sale. The update is preliminary and depends on the scope/timing of any transaction, which could drive sentiment for the company and potential M&A expectations.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.10
More News
- ‘I told you so’: China’s chip sector is making breakthroughs—and U.S. export controls are the reasons why
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- Hybe shares jump 10% as K-pop sensation BTS' tour lifts earnings hopes
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’
- What's behind the sell-off in AI neocloud stocks like CoreWeave and Nebius
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Evaluate Consensus Estimates Platforms With AI
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More